-
Toll-like receptor 9 (TLR9) genetic variants rs187084 and rs352140 confer protection from Behcet’s disease among Iranians BMC Rheumatol. Pub Date : 2024-03-14 Zahra Tadayon, Seyed Abolhassan Shahzadeh Fazeli, Nasser Gholijani, Gholamreza Daryabor
Behcet’s disease (BD) is a multisystem and multifactorial autoimmune disease characterized by relapsing episodes of oral aphthae, genital ulcers, and ocular and skin lesions. Toll-like receptor 9 (TLR9) has pro-inflammatory roles and its genetic variants might be involved in the pathogenesis of inflammatory diseases. Two hundred five BD patients and 207 age and sex-matched healthy controls were evaluated
-
Barriers and enablers to engagement in exercise and physical activity in non-English speaking South Asian people with chronic musculoskeletal disease BMC Rheumatol. Pub Date : 2024-03-11 Nasimah Maricar, Gillian Yeowell, Trixy David, Behram Khan, Anne Barton, Kimme L Hyrich, Sandra E Hartley
Exercise and physical activity (EPA) are recommended for people with chronic musculoskeletal disease; however, lower levels of engagement with EPA has been consistently reported in people from the South Asian community across a range of diseases. As language can pose a significant barrier in healthcare, this study aimed to understand the enablers and barriers to the acceptance of EPA among non-English
-
Methotrexate treatment strategies for rheumatoid arthritis: a scoping review on doses and administration routes BMC Rheumatol. Pub Date : 2024-03-05 Esteban Rubio-Romero, César Díaz-Torné, María José Moreno-Martínez, Julen De-Luz
To describe the evidence of methotrexate (MTX) initiation strategies in patients with rheumatoid arthritis (RA) and, in the case of non-responders, analyse the efficacy and safety of route and dose optimisation. We conducted a comprehensive scoping review of randomised controlled trials according to PRISMA Scoping Reviews Checklist and the framework proposed by Arksey and O’Malley. PubMed, EMBASE,
-
Patients’ experience of a novel interdisciplinary nurse-led self-management intervention (INSELMA)—a qualitative evaluation BMC Rheumatol. Pub Date : 2024-03-01 Nadine Schäffer Blum, Bente Appel Esbensen, Mikkel Østergaard, Ann Bremander, Oliver Hendricks, Luise Holberg Lindgren, Lena Andersen, Kim Vilbaek Jensen, Jette Primdahl
Despite continuous improvements in anti-rheumatic pharmacological treatment, people with chronic inflammatory arthritis still report substantial disease impact. Based on the framework for complex interventions, we thus developed INSELMA, a novel nurse-coordinated multidisciplinary self-management intervention for patients with rheumatoid arthritis, psoriatic arthritis or axial spondyloarthritis. Based
-
Association between Impella device support and elevated rates of gout flares: a retrospective propensity-matched study BMC Rheumatol. Pub Date : 2024-02-29 Jorge Sinclair De Frías, Shahin Isha, Lorenzo Olivero, Lekhya Raavi, Sai Abhishek Narra, Smit Paghdar, Sadhana Jonna, Parthkumar Satashia, Rachel Hannon, Jessica Blasavage, Layton White, Titilope Olanipekun, Pankaj Bansal, Sean Kiley, Juan Carlos Leoni, Jose Nativí, Melissa Lyle, Mathew Thomas, Basar Sareyyupoglu, Si Pham, Michael Smith, Pablo Moreno Franco, Parag Patel, Devang Sanghavi
Impella is an advanced ventricular assist device frequently used as a bridge to heart transplantation. The association of Impella with increased rates of gout flares has not been studied. Our primary aim is to determine the rates of gout flares in patients on Impella support. A retrospective study was conducted between January 2017 and September 2022 involving all patients who underwent heart transplantation
-
Participation in cardiovascular screening consultations, the who, when and why - A cohort study on patients with rheumatoid arthritis BMC Rheumatol. Pub Date : 2024-02-22 Julie Katrine Karstensen, Ann Bremander, Jeanette Reffstrup Christensen, Jette Primdahl
In accordance with the EULAR recommendations, the Danish Hospital for Rheumatic Diseases have systematically invited patients with rheumatoid arthritis (RA) to cardiovascular (CV) risk assessment since 2011. Patients with high risk are invited to a follow-up screening after one year. To optimize the screening and tailor it to individual needs, information about who accepts vs. declines follow-up is
-
An assessment of cardiovascular disease hospitalizations and disparities by race in patients with rheumatic disease hospitalizations in Alaska, 2015–2018 BMC Rheumatol. Pub Date : 2024-02-18 Elizabeth D. Ferucci, Peter Holck
There is an increased risk of cardiovascular disease in people with many rheumatic diseases. The primary objective of this study was to evaluate cardiovascular disease hospitalizations in Alaska for people with and without a rheumatic disease diagnosis and assess disparities by race, with a focus on Alaska Native and American Indian people. This study used the Alaska Health Facilities Data Reporting
-
Continuous improvement through differential trajectories of individual minimal disease activity criteria with guselkumab in active psoriatic arthritis: post hoc analysis of a phase 3, randomized, double-blind, placebo-controlled study BMC Rheumatol. Pub Date : 2024-02-04 Laura C. Coates, Proton Rahman, Philip J. Mease, May Shawi, Emmanouil Rampakakis, Alexa P. Kollmeier, Xie L. Xu, Soumya D. Chakravarty, Iain B. McInnes, Lai-Shan Tam
To explore the trajectory of, and factors contributing to, achievement of individual criteria of minimal disease activity (MDA) in patients with active psoriatic arthritis (PsA) treated with guselkumab. The Phase 3, randomized, placebo-controlled DISCOVER-2 study enrolled adults (N = 739) with active PsA despite standard therapies who were biologic/Janus kinase inhibitor-naive. Patients were randomized
-
Risk of venous thromboembolism in patients with rheumatoid arthritis: a meta-analysis of observational studies BMC Rheumatol. Pub Date : 2024-02-02 Zahra A Fazal, Ana Michelle Avina-Galindo, Shelby Marozoff, Jessie Kwan, Na Lu, J. Antonio Avina-Zubieta
Thrombotic events, such as venous thromboembolism (VTE) are a major health complication linked to rheumatoid arthritis (RA). We performed a meta-analysis to evaluate the risk of VTE, including deep vein thrombosis (DVT) and pulmonary embolism (PE), in adults with RA compared to the general population. MEDLINE and EMBASE databases were searched from inception to April 2022 to identify publications meeting
-
Janus kinase inhibitors vs. abatacept about safety and efficacy for patients with rheumatoid arthritis-associated interstitial lung disease: a retrospective nested case-control study BMC Rheumatol. Pub Date : 2024-01-26 Atsuko Tsujii, Kentaro Isoda, Maiko Yoshimura, Akihiko Nakabayashi, Dong-Seop Kim, Tatsuya Tamada, Kurumi Yamamoto, Shiro Ohshima
Interstitial lung disease (ILD) related to rheumatoid arthritis (RA) is among the leading causes of death and an essential prognostic factor. There is only limited evidence for the safety of anti-rheumatic drugs for patients with RA-ILD. The aim of this study is to investigate the safety and efficacy of Janus kinase inhibitors (JAKis) by comparing it with abatacept (ABT) in patients with RA-ILD. This
-
The efficacy of tofacitinib combined with bDMARDs in the treatment of ankylosing spondylitis patients with inadequate response to bDMARDs: a retrospective study BMC Rheumatol. Pub Date : 2024-01-25 Jie Chang, Gang Wang
Ankylosing spondylitis(AS) is a chronic inflammatory rheumatic disease primarily affecting the spine and sacroiliac joints. While biologic disease-modifying antirheumatic drugs(bDMARDs) and targeted synthetic DMARDs(tsDMARDs) are popular treatments for AS, there is limited research on their combined use. This study examined a cohort of AS patients who demonstrated inadequate response to bDMARDs and
-
Cross-sectional association between social and demographic factors and disease activity in rheumatoid arthritis BMC Rheumatol. Pub Date : 2024-01-19 Lei Zhu, Larry W. Moreland, Dana Ascherman
This study aimed to assess the association between social factors, demographic parameters, and disease activity among rheumatoid arthritis (RA) patients. The University of Pittsburgh Rheumatoid Arthritis Comparative Effectiveness Research (RACER) registry was used for this study and included patients meeting 1987 ACR criteria for RA enrolled between 2010–2015. The registry collected clinical and laboratory
-
Clinician and patient views on janus kinase inhibitors in the treatment of inflammatory arthritis: a mixed methods study BMC Rheumatol. Pub Date : 2024-01-17 Savia de Souza, Ruth Williams, Elena Nikiphorou
Janus kinase inhibitors (JAKi) are new targeted synthetic disease-modifying antirheumatic drugs (DMARDs) licenced in the UK to treat rheumatoid and psoriatic arthritides. Unlike currently often prescribed biological DMARDs, they target a different part of the inflammatory pathway and are taken orally. The aim of this study was to explore what UK-based rheumatology clinicians and inflammatory arthritis
-
The study of serum muscarinic acetylcholine receptor subtype 3 (m3AChR)-Specific autoantibodies level in rheumatoid arthritis patients with secondary sjogren syndrome BMC Rheumatol. Pub Date : 2023-12-18 Hagar Elsayed Fakher, Nagat Mohammed El Gazzar, Maaly Mohamed Mabrouk, Doaa Waseem Nada
Dry eyes and mouth are symptoms of Sjogren syndrome, which can occur on its own and be referred to as primary Sjogren syndrome or in conjunction with other rheumatic diseases like rheumatoid arthritis and be referred to as secondary Sjogren syndrome. Anti-muscarinic type 3 receptors have been linked to neurological issues as well as secretory dysfunction in Sjogren patients. Consequently, the purpose
-
Decoding the mitochondrial connection: development and validation of biomarkers for classifying and treating systemic lupus erythematosus through bioinformatics and machine learning BMC Rheumatol. Pub Date : 2023-12-04 Haoguang Li, Lu Zhou, Wei Zhou, Xiuling Zhang, Jingjing Shang, Xueqin Feng, Le Yu, Jie Fan, Jie Ren, Rongwei Zhang, Xinwang Duan
Systemic lupus erythematosus (SLE) is a multifaceted autoimmune disease characterized by clinical and pathological diversity. Mitochondrial dysfunction has been identified as a critical pathogenetic factor in SLE. However, the specific molecular aspects and regulatory roles of this dysfunction in SLE are not fully understood. Our study aims to explore the molecular characteristics of mitochondria-related
-
Cardiovascular disease risk in early rheumatoid arthritis: the impact of cartilage oligomeric matrix protein (COMP) and disease activity BMC Rheumatol. Pub Date : 2023-12-01 Emil Rydell, Lennart TH Jacobsson, Tore Saxne, Carl Turesson
To investigate whether baseline serum cartilage oligomeric matrix protein (COMP), patient characteristics, traditional cardiovascular disease (CVD) risk factors and disease activity over time predict CVD, in early rheumatoid arthritis (RA). This study included patients with early RA (< 12 months disease duration) (n = 233) recruited 1995–2005. Potential predictors of CVD and coronary artery disease
-
Osteonecrosis as a rare musculoskeletal complication in Behcet’s disease- the largest case series with literature review BMC Rheumatol. Pub Date : 2023-11-30 Mohammad Nejadhosseinian, Mazyar Babagoli, Seyedeh Tahererh Faezi, Hoda Haerian, Farhad Shahram, Majid Alikhani, Fereydoun Davatchi
Behcet disease (BD) as a variable vessel vasculitis is mainly characterized by ocular involvement, genital and oral aphthosis, and erythema nodosum. However, major organ involvements including gastrointestinal involvement, nervous system, and vascular involvement are among the severe complications. Osteonecrosis is a rare complication of patients with BD. We aim to report the largest series of BD patients
-
Employment of patients with rheumatoid arthritis - a systematic review and meta-analysis BMC Rheumatol. Pub Date : 2023-11-14 Lilli Kirkeskov, Katerina Bray
Patients with rheumatoid arthritis (RA) have difficulties maintaining employment due to the impact of the disease on their work ability. This review aims to investigate the employment rates at different stages of disease and to identify predictors of employment among individuals with RA. The study was carried out according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA)
-
Efficacy and safety of baricitinib in treatment of systemic lupus erythematosus: a systematic review and meta-analysis BMC Rheumatol. Pub Date : 2023-10-31 Abdallah R. Allam, Mohamed Salah Alhateem, Abdelrahman Mohamed Mahmoud
SLE is an autoimmune disease marked by broad immunological dysregulation and multi-system inflammation. Baricitinib is one of the novel treatments for SLE. We conducted this meta-analysis to evaluate its safety and effectiveness in treating SLE. We looked for all published randomized controlled trials in PubMed, Scopus, Web of Science, and Cochrane and included all RCTs comparing baricitinib and placebo
-
Inflammasomes in rheumatoid arthritis: a pilot study BMC Rheumatol. Pub Date : 2023-10-30 Qi Jiang, Xin Wang, Xiuping Xu, Liangfeng Hu, Guozhong Zhou, Rui Liu, Guocan Yang, Dawei Cui
The inflammasome plays an important role in rheumatoid arthritis (RA), which has rarely been systematically reported. The aim of this study was to understand whether the levels of inflammasomes were related to the severity of RA disease, which might provide a stronger theoretical basis for RA treatment. The mRNA expression levels of some inflammasomes and associated molecules, including IL-1beta and
-
Face validity and reliability test of the Danish version of the compliance questionnaire rheumatology in patients with early rheumatoid arthritis BMC Rheumatol. Pub Date : 2023-10-25 Line Raunsbæk Knudsen, Annette de Thurah
Supporting adherence to medication is an essential part of the treatment and care of patients with rheumatic and musculoskeletal diseases. The Compliance Questionnaire Rheumatology (CQR) measures adherence in rheumatic diseases through 19 items covering drug-taking behaviour to identify the reasons for adhering to treatment and the factors that contribute to suboptimal adherence. The objective of this
-
Safety and efficacy of biological agents in the treatment of Systemic Lupus Erythematosus (SLE) BMC Rheumatol. Pub Date : 2023-10-09 Justin Chan, Giles D. Walters, Prianka Puri, Simon H. Jiang
To determine the safety and efficacy of biological agents used in the treatment of systemic lupus erythematosus (SLE) in adults. Systematic review and meta-analysis following PRISMA guidelines. MEDLINE (through Pubmed), EMBASE, Cochrane library, Clinicaltrials.gov, Australianclinicaltrials.gov.au, ANZCTR.org.au and WHO International Clinical Trials Registry Platform for studies published from 20 May
-
The student patient alliance: development and formative evaluation of an initiative to support collaborations between patient and public involvement partners and doctoral students BMC Rheumatol. Pub Date : 2023-10-03 Gwenda Simons, Rebecca Birch, Joanne Stocks, Elspeth Insch, Rob Rijckborst, Georgiana Neag, Heidi McColm, Leigh Romaniuk, Claire Wright, Bethan E. Phillips, Simon W. Jones, Arthur G. Pratt, Stefan Siebert, Karim Raza, Marie Falahee
While the integration of patient and public involvement (PPI) in clinical research is now widespread and recommended as standard practice, meaningful PPI in pre-clinical, discovery science research is more difficult to achieve. One potential way to address this is by integrating PPI into the training programmes of discovery science postgraduate doctoral students. This paper describes the development
-
Stakeholder perceptions of preventive approaches to rheumatoid arthritis: qualitative study of healthcare professionals’ perspectives on predictive and preventive strategies BMC Rheumatol. Pub Date : 2023-10-03 Imogen Wells, Gwenda Simons, Jasin Philip Kanacherril, Christian D. Mallen, Karim Raza, Marie Falahee
There is increasing research interest in the development of preventive treatment for individuals at risk of rheumatoid arthritis (RA). Previous studies have explored the perceptions of at-risk groups and patients about predictive and preventive strategies for RA, but little is known about health care professionals’ (HCPs) perspectives. One-to-one semi-structured qualitative interviews were conducted
-
Pericardial effusions and cardiac tamponade in hospitalized systemic sclerosis patients: analysis of the national inpatient sample BMC Rheumatol. Pub Date : 2023-09-28 Bikash Basyal, Waqas Ullah, Chris T. Derk
Clinically significant pericardial effusions and cardiac tamponade in systemic sclerosis (SSc) patients is uncommon and the factors that contribute to progression of pericardial involvement in SSc patients have not been well established. A review of the national inpatient sample database was performed looking SSc related hospitalizations between 2002 and 2019. Data was collected on patients with pericardial
-
Heterogeneity of treatment responses in rheumatoid arthritis using group based trajectory models: secondary analysis of clinical trial data BMC Rheumatol. Pub Date : 2023-09-25 Fowzia Ibrahim, Ian C Scott, David L Scott, Salma Ahmed Ayis
Traditionally rheumatoid arthritis (RA) trials classify patients as responders and non-responders; they ignore the potential range of treatment responses. Group Based Trajectory Models (GBTMs) provide a more refined approach. They identify patient subgroups with similar outcome trajectories. We used GBTMs to classify patients into subgroups of varying responses and explore factors associated with different
-
Implementation of a hybrid healthcare model in rheumatic musculoskeletal diseases: 6-months results of the multicenter Digireuma study BMC Rheumatol. Pub Date : 2023-09-25 D. Benavent, L. Fernández-Luque, M. Sanz-Jardón, I. Bilionis, M. Novella-Navarro, V. Navarro-Compán, P. L. González-Sanz, E. Calvo, L. Lojo, A. Balsa, Ch Plasencia-Rodríguez
Rheumatic and musculoskeletal diseases (RMDs) require a tailored follow-up that can be enhanced by the implementation of innovative tools. The Digireuma study aimed to test the feasibility of a hybrid follow-up utilizing an electronic patient reported outcomes (ePROs)-based monitoring strategy in patients with RMDs. Adult patients with rheumatoid arthritis (RA) and spondyloarthritis (SpA) were recruited
-
Effectiveness and cost-effectiveness of a multimodal, physiotherapist-led, vocational intervention in people with inflammatory arthritis: study protocol of the Physiotherapy WORKs trial BMC Rheumatol. Pub Date : 2023-09-20 N. F. Bakker, S. F. E. van Weely, N. Hutting, Y. F. Heerkens, J. A. Engels, J. B. Staal, M. van der Leeden, A. Boonen, W. B. van den Hout, T. P. M. Vliet Vlieland, J. Knoop
Although reduced work ability is a substantial problem among people with inflammatory arthritis (IA), work ability is an underexposed area in clinical practice. Evidence on vocational interventions in IA is limited, but favourable results of delivery by a physiotherapist (PT) warrant the need for further research. Therefore, we aim to evaluate the (cost-)effectiveness of a multimodal, PT-led, vocational
-
Cardiac sarcoma presenting as paraneoplastic arthritis and clubbing: a case report and literature review BMC Rheumatol. Pub Date : 2023-09-15 Natasha Ung, Carmella Gunasingam, Ken Cai, Nicholas Manolios, Angela Bayly, Phuong Dinh, Yishay Orr, Preeti Choudhary, Peter Wong
Cardiac tumours are rare, and clinical manifestations depend on the anatomical location. Symptoms can be the result of cardiac outflow anomalies, constitutional features such as fever, loss of weight, and/or paraneoplastic manifestations such as arthritis. To date, there has only been one other case report in the literature of cardiac sarcoma presenting as paraneoplastic arthropathy. A 52-year-old
-
Correlation of serum subfatin, cthrc1, ctrp3, ctrp6 levels with disease indices in patients with axial spondyloarthritis BMC Rheumatol. Pub Date : 2023-09-14 İ.Merve B. Uçar, Gökhan Sargin, Ayça Tuzcu, Songül Çildağ, Taşkın Şentürk
The study aimed to investigate novel biomarkers from the C1q TNF superfamily and evaluate their role in autoimmune inflammatory rheumatic diseases with the goal of identifying an effective biomarker to measure clinical disease activity and assess treatment efficacy. Sixty-one Axial spondyloarthritis (AxSpa) patients and 30 healthy controls were enrolled in the study. The serum biomarkers subfatin,
-
Osteoporosis-related fractures in men and women with established and early rheumatoid arthritis: predictors and risk compared with the general population BMC Rheumatol. Pub Date : 2023-09-08 Lisa Theander, Lennart T.H. Jacobsson, Carl Turesson
To study the risk of osteoporosis-related fractures in a community-based sample of men and women with rheumatoid arthritis (RA) overall, as well as early (< 1 year of disease duration, follow-up time maximum 10 years) and established (RA diagnosis since ≥ 5 years on July 1, 1997) RA, compared with the general population. To study potential risk factors for fractures in patients with RA from baseline
-
Effects of lifestyle physical activity and sedentary behaviour interventions on disease activity and patient- and clinician- important health outcomes in rheumatoid arthritis: a systematic review with meta-analysis BMC Rheumatol. Pub Date : 2023-09-06 Sophia M. Brady, Jet J. C. S. Veldhuijzen van Zanten, Petros C. Dinas, Tom E. Nightingale, George S. Metsios, Saleh M. A. Elmsmari, Joan L. Duda, George D. Kitas, Sally A. M. Fenton
Lifestyle physical activity (PA) is defined as any type of PA undertaken as part of daily life. It can include engagement in activities of daily living (i.e., household chores, gardening, walking to work), incidental PA, walking and/or reducing sedentary or sitting behaviours (SB). Regular PA is recommended for people with Rheumatoid Arthritis (RA) to reduce disease activity and systemic inflammation
-
Exploring the emotional impact of axial Spondyloarthritis: a systematic review and thematic synthesis of qualitative studies and a review of social media BMC Rheumatol. Pub Date : 2023-08-23 Nicky Wilson, Jia Liu, Qainat Adamjee, Sonya Di Giorgio, Sophia Steer, Jane Hutton, Heidi Lempp
The psychological burden in people with inflammatory arthritis is substantial, yet little is known about the disease-related affect experienced by individuals with axial Spondyloarthritis (axial SpA). The aim of this study was to conduct a qualitative evidence synthesis and a review of social media to explore the emotional impact of living with axial SpA. We searched nine databases for studies reporting
-
Potential gastrointestinal Behcet’s disease flare after treatment with anti-interleukin 17a therapy BMC Rheumatol. Pub Date : 2023-08-08 Frances Sze Kei Sun, Nicole Sau Yan Chiu, Ho Yin Chung
Behcet’s disease (BD) is a systemic disease characterized by recurrent oral and genital ulcers. The underlying disease pathway likely involves interleukin (IL)-17 A, a proinflammatory cytokine that is implicated in Behcet’s uveitis. Secukinumab is an anti-IL-17 A drug that may have an emerging role in the treatment of refractory BD. This is the first known case report of gastrointestinal BD flare up
-
Clinical diagnoses associated with a positive antinuclear antibody test in patients with and without autoimmune disease BMC Rheumatol. Pub Date : 2023-08-07 Jacy T. Zanussi, Juan Zhao, Wei-Qi Wei, Gul Karakoc, Cecilia P. Chung, QiPing Feng, Nancy J. Olsen, C. Michael Stein, Vivian K. Kawai
Antinuclear antibodies (ANA) are antibodies present in several autoimmune disorders. However, a large proportion of the general population (20%) also have a positive test; very few of these individuals will develop an autoimmune disease, and the clinical impact of a positive ANA in them is not known. Thus, we test the hypothesis that ANA + test reflects a state of immune dysregulation that alters risk
-
Long-term fracture risk in rheumatoid arthritis: impact of early sustained DAS28-remission and restored function, progressive erosive disease, body mass index, autoantibody positivity and glucocorticoids. A cohort study over 10 years BMC Rheumatol. Pub Date : 2023-08-07 Sofia Ajeganova, Maria Andersson, Kristina Forslind, Inger Gjertsson, Britt-Marie Nyhäll-Wåhlin, Björn Svensson, Ingiäld Hafström
Risk of fragility fractures in patients with rheumatoid arthritis (RA) is increased. Disease-related inflammation in RA is associated with low Bone Mineral Density (BMD). However, effects of specific disease factors on fracture occurrence and whether or not such disease effects are independent of BMD are unknown. Analysis of fracture outcome in the prospective cohort of 2557 patients with early RA
-
Occurrence and outcome of COVID-19 in AIRD patients on concomitant treatment with Tofacitinib- results from KRA COVID COHORT (KRACC) subset BMC Rheumatol. Pub Date : 2023-07-26 Pramod Chebbi, Vineeta Shobha, Vijay K Rao, Vikram Haridas, Ramya Janardana, Benzeeta Pinto, Sharath Kumar, Abhishek Patil, Roopa Tekkatte, Manasa Salanke, K M Mahendranath
We assessed the risk factors and outcome of COVID-19 in patients with autoimmune rheumatic diseases(AIRD) who contracted infection while on background treatment with tofacitinib. This is a non-interventional, cross-sectional, questionnaire based telephonic study which included consecutive AIRD patients on tofacitinib co-treatment. Data related to the AIRD subset, disease modifying anti rheumatic drugs(DMARDs)
-
Sleep quality and clinical association with sleep disturbance in systemic sclerosis BMC Rheumatol. Pub Date : 2023-07-21 Nonthaphorn Wongthawa, Apichart So-gnern, Ajanee Mahakkanukrauh, Siraphop Suwannaroj, Chingching Foocharoen
Poor sleep quality is a common and potentially debilitating problem in systemic sclerosis (SSc). To date, no data clarifies the potential factors related to poor sleep quality and the clinical associations with sleep disturbance among Thais with SSc—mainly the diffuse cutaneous SSc (dcSSc) subset. We aimed to evaluate sleep quality and identify the clinical association with sleep disturbance among
-
Comparison of anti-spike IgG, anti-spike IgA levels and neutralizing antibody activity induced by CoronaVac and BNT162b2 vaccines in patients with inflammatory rheumatic diseases receiving immunosuppressive therapy BMC Rheumatol. Pub Date : 2023-07-19 Fulya Cosan, Ozlem Unay Demirel, Demet Yalcin, Muhammed Mert Sonkaya, Isilsu Ezgi Uluisik, Olida Cecen, Yavuz Furuncuoglu, Deniz Maktav Celikmen, Osman Kara, Erkan Ceylan, Timucin Avsar
The importance of COVID-19 vaccination for patients on immunosuppressive (IS) medication has increased due to the high risk of severe disease or mortality. Different vaccines have varying efficacy rates against symptomatic COVID-19, ranging from 46.8% to 95%. The objective of this study was to examine the differences in anti-Spike IgG, anti-Spike IgA, and neutralizing antibody (NAb) activity between
-
Scarcity in abundance? Spatial inequalities in Rheumatoid Arthritis in a health system with financial equity BMC Rheumatol. Pub Date : 2023-07-11 Norman Maldonado, Sandra Camacho, Sergio I. Prada, Andrés Hormaza-Jaramillo, Victoria Soto, William García, Nelcy Paredes, Fabián Cardona
This paper estimates spatial inequalities of Rheumatoid Arthritis (RA) in Colombia and explores correlates of those disparities from a health system perspective. We apply descriptive epidemiology to healthcare administrative records for estimation of crude and age-standardized prevalences, and health systems thinking for identification of barriers to effective access in RA diagnosis. The crude and
-
A case of VEXAS syndrome presenting with unusual bone marrow granulomas: a diagnostic dilemma BMC Rheumatol. Pub Date : 2023-07-10 Khiem T. Vu, Rachel M. Wolfe, Jonathan E. Lambird, Danielle L. V. Maracaja
VEXAS is a recently described inflammatory disease caused by mutations in the UBA1 gene. Symptoms are diverse and include fevers, cartilaginous inflammation, lung inflammation, vasculitis, neutrophilic dermatoses, and macrocytic anemia. Cytoplasmic inclusions in myeloid and erythroid progenitors in the bone marrow are a hallmark feature. Here we report the first case of VEXAS with non-caseating granulomas
-
Physical function and severe side effects matter most to patients with RA (< 5 years): a discrete choice experiment assessing preferences for personalized RA treatment BMC Rheumatol. Pub Date : 2023-07-03 Karin Schölin Bywall, Bente Appel Esbensen, Marie Heidenvall, Inger Erlandsson, Marta Lason, Mats Hansson, Jennifer Viberg Johansson
Early assessment of patient preferences has the potential to support shared decisions in personalized precision medicine for patients with rheumatoid arthritis (RA). The aim of this study was to assess treatment preferences of patients with RA (< 5 years) with previous experience of inadequate response to first-line monotherapy. Patients were recruited (March–June 2021) via four clinics in Sweden.
-
Determinants of health-related quality of life among patients with systemic lupus erythematosus in Hanoi, Vietnam BMC Rheumatol. Pub Date : 2023-06-22 Aya Mizukami, Minh Trang Trinh, Thi Phuong Hoang, Akira Shibanuma, Ken Ing Cherng Ong, Masamine Jimba
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease which impacts patients’ lives. Many studies in high-income countries have focused on their health-related quality of life (HRQoL). However, evidence of awareness of SLE and HRQoL in low- and middle-income countries is lacking. Therefore, this study aimed to identify the determinants of HRQoL of SLE patients in Vietnam, a lower-middle
-
What are the core recommendations for gout management in first line and specialist care? Systematic review of clinical practice guidelines BMC Rheumatol. Pub Date : 2023-06-15 Brooke Conley, Samantha Bunzli, Jonathan Bullen, Penny O’Brien, Jennifer Persaud, Tilini Gunatillake, Michelle M Dowsey, Peter F Choong, Mandana Nikpour, Rebecca Grainger, Ivan Lin
Gout is the most common inflammatory arthritis, increasing in prevalence and burden. Of the rheumatic diseases, gout is the best-understood and potentially most manageable condition. However, it frequently remains untreated or poorly managed. The purpose of this systematic review is to identify Clinical Practice Guidelines (CPG) regarding gout management, evaluate their quality, and to provide a synthesis
-
Prediction of risk of ischemic heart disease in first-diagnosed systemic lupus erythematosus patients in taiwan: is air pollution exposure a risk factor? BMC Rheumatol. Pub Date : 2023-06-08 Pei-Yun Chen, Yu-Tse Tsan, Chao-Tung Yang, Yun-Mei Lee, Li-Li Chen, Wen-Chao Ho, Shu-Hua Lu
Air pollution is a key public health factor with the capacity to induce diseases. The risk of ischemia heart disease (IHD) in those suffering from systemic lupus erythematosus (SLE) from air pollution exposure is ambiguous. This study aimed to: (1) determine the hazard ratio (HR) of IHD after the first-diagnosed SLE and (2) examine the effects of air pollution exposure on IHD in SLE for 12 years. This
-
Radiographic involvement of cervical facet joints in ankylosing spondylitis: a longitudinal analysis in correlation with vertebral body lesions BMC Rheumatol. Pub Date : 2023-06-07 Tae-Han Lee, Seunghun Lee, Bon San Koo, Kyung Bin Joo, Tae-Hwan Kim
The inability to assess structural changes in facet joints is a limitation of established radiographic scoring systems for ankylosing spondylitis (AS). We compared radiographic evidence of ankylosis in cervical facet joints and cervical vertebral bodies in patients with AS. We analysed longitudinal data collected from 1106 AS patients and assessed 4984 spinal radiographs obtained up to 16 years of
-
Attitudes and beliefs towards COVID-19 and COVID-19 vaccination among rheumatology patients in a Los Angeles County safety net clinic BMC Rheumatol. Pub Date : 2023-06-01 Nicole K. Zagelbaum Ward, Suman Pal, Katherine Ruddy, Stavros Savvas
The novel Coronavirus disease (COVID-19) pandemic has represented an evolving global threat with high morbidity and mortality. Patients with autoimmune rheumatic diseases and on immune-suppressing medications may be at increased risk to more severe disease, hospitalization, and death. Vaccines are essential to combat the COVID-19 pandemic and curb the spread of infection. Rheumatology patients may
-
Patient and public involvement in rheumatic and musculoskeletal research: an idea whose time has firmly come BMC Rheumatol. Pub Date : 2023-05-31 Angie Botto-van Bemden, Adewale O. Adebajo, Ciarán Martin Fitzpatrick
Patient and public involvement is an idea whose time has firmly come. It is the views of these Guest Editors that it is the right thing to do morally and improves research quality and applicability.
-
Predictors of severe lupus flare: a prospective follow-up study BMC Rheumatol. Pub Date : 2023-05-24 Alimohammad Fatemi, Elaheh Keivani-Boroujeni, Abbas Smiley
Flare-up of systemic lupus erythematosus (SLE) is a common characteristic that could have deleterious effects on patients’ outcome and survival. The aim of this study was to identify the predictors of severe lupus flare. 120 patients with SLE were enrolled and followed-up for 23 months. Demographic, clinical manifestations, laboratory parameters and disease activity were recorded at each visit. In
-
Hands and feet radiologic involvements in systemic sclerosis BMC Rheumatol. Pub Date : 2023-05-20 Fatemeh Badiee, Alireza Fatemi, Reza Zahedpasha, Mohammad Hadi Gharib, Mohammadhassan Jokar, Somayeh Livani, Mehrdad Aghaie, Nafiseh Abdolahi
Systemic sclerosis (SSc) is a rare autoimmune disorder characterized by vascular and fibrosing involvement of the skin and internal organs. In this study, we determined the prevalence and characteristics of radiological hands and feet involvements in Iranian SSc patients to identify the associations between clinical features and radiologic findings. 43 SSc patients (41 women and 2 men), with a median
-
Concomitant prednisone may alleviate methotrexate side-effects in rheumatoid arthritis patients BMC Rheumatol. Pub Date : 2023-05-17 Matthijs S. van der Leeuw, Janneke Tekstra, Jacob M. van Laar, Paco M. J. Welsing
To evaluate whether addition of low-moderate dose prednisone to methotrexate (MTX) treatment can alleviate common MTX side-effects in rheumatoid arthritis (RA) patients. We performed a post-hoc analysis of the CAMERA-II trial which randomized (1:1) 236 early DMARD and prednisone naive RA patients to treatment with MTX + prednisone 10 mg daily, or MTX monotherapy during two years. MTX dose was increased
-
Drug-related problems reported by patients with rheumatic diseases: an observational study BMC Rheumatol. Pub Date : 2023-04-18 Lex L. Haegens, Victor J. B. Huiskes, Elisabeth M. Smale, Charlotte L. Bekker, Bart J. F. van den Bemt
Drug-related problems can negatively influence treatment outcome and well-being for patients with rheumatic diseases. Thus, it is important to support patients in preventing or resolving drug-related problems as quickly as possible. To effectively develop interventions for this purpose, knowledge on the frequency and character of drug-related problems is needed. Therefore, this study aims to quantify
-
Chasing the Zebra: a case of membranous-like Glomerulopathy with SSA/RO52 deposits and no overt connective tissue disease BMC Rheumatol. Pub Date : 2023-04-05 Savino Sciascia, Paolo Miraglia, Massimo Radin, Manuela Giarin, Nicolas Charbonier, Antonella Barreca, Irene Cecchi, Irene Lanzetta, Roberta Fenoglio, Elisa Menegatti, Dario Roccatello
The nature of the deposits in immune-mediated glomerulonephritis with a membranous pattern and masked IgG-Kappa deposits (MGMID) remains still to be elucidated. We present a case of 33-year-old woman developing a continuous asymptomatic proteinuria (0.8–1 g/24 h) with no overt connective tissue diseases. She tested positive at high titers for SSA antibodies (Ro52 838 UI/mL, Ro60 2716 UI/mL) and at
-
Effectiveness and safety of intravenous golimumab with and without concomitant methotrexate in patients with rheumatoid arthritis in the prospective, noninterventional AWARE study BMC Rheumatol. Pub Date : 2023-03-27 Aaron Broadwell, Joy Schechtman, Douglas Conaway, Alan Kivitz, Natalie J. Shiff, Shawn Black, Stephen Xu, Wayne Langholff, Sergio Schwartzman, Jeffrey R. Curtis
Biologic therapies are often prescribed for patients with rheumatoid arthritis (RA) who have inadequate responses to or are intolerant of methotrexate (MTX) and patients with poor prognostic indicators. This post hoc analysis evaluated effectiveness and safety of intravenous golimumab + MTX vs golimumab without MTX in RA patients. AWARE, a real-world, prospective and pragmatic, Phase 4 study, compared
-
Comprehensive evaluation of the influence of sex differences on composite disease activity indices for rheumatoid arthritis: results from a nationwide observational cohort study BMC Rheumatol. Pub Date : 2023-03-21 Takahiro Nishino, Atsushi Hashimoto, Shigeto Tohma, Toshihiro Matsui
The effects and their magnitudes of sex on disease activity indices for rheumatoid arthritis are not clear. We aimed to comprehensively evaluate the influence of sex on disease activity indices in the real-world setting using a large observational database. We analyzed 14,958 patients registered in the National Database of Rheumatic Diseases in Japan (NinJa) in 2017. We evaluated the sex differences
-
Vitamin D status and risk of rheumatoid arthritis: systematic review and meta-analysis BMC Rheumatol. Pub Date : 2023-03-15 Joanna L. Clasen, Rachel Cole, Dagfinn Aune, Edward Sellon, Alicia K. Heath
Vitamin D is important for immunomodulation and may play a role in autoimmune diseases. Studies have reported a high prevalence of vitamin D deficiency in rheumatoid arthritis (RA) patients, and vitamin D status, assessed by circulating 25-hydroxyvitamin D [25(OH)D] concentration, is inversely associated with RA disease activity. However, it is unclear whether vitamin D deficiency increases the risk
-
Patient and public involvement in research: a review of practical resources for young investigators BMC Rheumatol. Pub Date : 2023-03-09 Ashokan Arumugam, Lawrence Rick Phillips, Ann Moore, Senthil D. Kumaran, Kesava Kovanur Sampath, Filippo Migliorini, Nicola Maffulli, Bathri Narayanan Ranganadhababu, Fatma Hegazy, Angie Botto-van Bemden
Patient and public involvement (PPI) in every aspect of research will add valuable insights from patients’ experiences, help to explore barriers and facilitators to their compliance/adherence to assessment and treatment methods, bring meaningful outcomes that could meet their expectations, needs and preferences, reduce health care costs, and improve dissemination of research findings. It is essential
-
Patient participation in defining best-practice rheumatology service provision in Aotearoa New Zealand: a qualitative study with service consumers BMC Rheumatol. Pub Date : 2023-01-24 Rachel Ngan Kee, Valerie Milne, Nicola Dalbeth, Rebecca Grainger
Aotearoa New Zealand (AoNZ) has no agreed models for rheumatology service provision in government-funded health care. We aimed to describe what people with inflammatory rheumatic diseases who have used rheumatology services view as being important in those services, and map these views to previously collated statements describing best practice components of rheumatology services from international
-
The prevalence of rheumatoid arthritis in Western Australia BMC Rheumatol. Pub Date : 2022-12-31 Almutairi, Khalid, Inderjeeth, Charles, Preen, David B, Keen, Helen, Nossent, Johannes
Rheumatoid arthritis (RA) is the most common form of autoimmune arthritis, but the prevalence in Australia is unknown. We estimated RA period prevalence and identified factors associated with frequent RA hospitalisations, using linked administrative health and state-specific Australian Pharmaceutical Benefits Scheme (PBS) datasets in Western Australia (WA) from 1995 to 2014. This was a longitudinal
-
Formative research to promote lupus awareness and early screening at Historically Black College and University (HBCU) communities in South Carolina BMC Rheumatol. Pub Date : 2022-12-31 Williams, Edith M., Nelson, Joni, Francis, Diane, Corbin, Keesha, Link, Gary, Caldwell, Tomika, Gilkeson, Gary
Systemic lupus erythematosus or lupus is a severe chronic autoimmune disorder that disproportionately impacts young African Americans. Increasing lupus awareness in this high-risk group may be an effective approach to ultimately improving lupus outcomes. To begin to address this disparity, this report describes qualitative data to be utilized in the development of a campaign to enhance awareness of